Which serum tumor markers and tissue molecular alterations should be assessed in a patient with lung adenocarcinoma for diagnosis, treatment selection, and disease monitoring?

Lung Adenocarcinoma Markers: Tissue Molecular Testing and Serum Biomarkers

Mandatory Tissue Molecular Testing

All patients with lung adenocarcinoma must undergo comprehensive molecular testing for EGFR, ALK, and ROS1 at minimum, with broader panel testing strongly recommended to include BRAF, RET, MET, ERBB2 (HER2), and KRAS. 1

Essential Molecular Alterations (Must Test)

• EGFR mutations: Test all adenocarcinomas regardless of smoking status, age, sex, or ethnicity 1

  • Minimum testing must cover exon 19 deletions and exon 21 L858R substitution 1
  • Complete sequencing of exons 18-21 by NGS is strongly recommended to identify all sensitizing mutations including exon 18 G719X 1
  • EGFR IHC and FISH have no clinical utility and should not be performed 1
  • Prevalence: 10% in Western populations, up to 50% in Asian patients 1

• ALK rearrangements: Mandatory testing for all adenocarcinomas 1

  • IHC is an acceptable alternative to FISH for ALK testing; treatment decisions can be made on clearly positive IHC without molecular confirmation 1, 2
  • Prevalence: approximately 3-5% of NSCLC 1

• ROS1 rearrangements: Must be tested in all advanced adenocarcinomas 1, 3

  • FISH, RT-PCR, or NGS are acceptable confirmatory methods 1, 3
  • ROS1 IHC may be used as screening only; all positive results require molecular confirmation before treatment 1, 2, 3
  • Critical pitfall: Never initiate ROS1-targeted therapy based solely on IHC 3
  • Prevalence: 2-2.4% of adenocarcinomas 1

Recommended Extended Panel Testing

When adequate tissue is available, include these alterations in initial testing: 1

• BRAF mutations: Test all advanced adenocarcinomas; V600E mutations occur in ~0.8-2% 1
• RET rearrangements: Include in larger panels; found in 1-2% of adenocarcinomas 1
• MET exon 14 skipping: Include in comprehensive panels; present in 2-4% 1
• ERBB2 (HER2) mutations: Include in panels; found in 2-4% 1
• KRAS mutations: Most common in Western populations (25-30%), associated with smoking and mucinous histology 1
  • KRAS G12C mutations (16% of early-stage adenocarcinomas) are now targetable 4
  • KRAS testing may be used to exclude patients from expanded panel testing in sequential algorithms 1
• NTRK fusions: Include in comprehensive panels despite low frequency (<1%) due to availability of effective targeted therapy 1

Testing at Disease Progression

• EGFR T790M mutation: Mandatory testing at progression on first- or second-generation EGFR TKIs 1
  • Cell-free DNA (cfDNA) testing is appropriate for patients unable/unwilling to undergo repeat biopsy 1
  • Critical limitation: cfDNA has intermediate sensitivity (40-78%) but high specificity; negative cfDNA requires tissue confirmation 1
  • Positive cfDNA T790M is equivalent to tissue biopsy and can guide osimertinib therapy 1

Immunohistochemistry for Diagnosis and Subtyping

A limited two-marker IHC panel (TTF-1 and p40) should be used for NSCLC subtyping when morphology is insufficient, with the goal of reducing NSCLC-NOS diagnoses to <10%. 2

Diagnostic IHC Panel

• TTF-1: Positive in 70-100% of non-mucinous adenocarcinomas; indicates lung primary 1, 2
• Napsin A: Expressed in >80% of lung adenocarcinomas; useful adjunct to TTF-1 1
• p40: Positive indicates squamous cell carcinoma 2
• Interpretation: TTF-1+/p40- = adenocarcinoma; TTF-1-/p40+ = squamous; both negative = NSCLC-NOS 2

Distinguishing Primary from Metastatic Disease

When evaluating adenocarcinoma in lung, use IHC panel including TTF-1, Napsin A, CK7, and CK20 to exclude metastatic carcinoma 1, 2

PD-L1 Testing for Immunotherapy Selection

PD-L1 IHC testing is essential for selecting patients for immune checkpoint inhibitor therapy, but requires drug-specific companion or complementary diagnostic assays. 1, 2

Drug-Specific PD-L1 Assays

• Pembrolizumab: Requires PD-L1 IHC 22C3 assay (companion diagnostic) 1, 2
• Nivolumab: Uses PD-L1 IHC 28-8 assay (complementary diagnostic) 1, 2
• Atezolizumab: Uses PD-L1 IHC SP142 assay (complementary diagnostic) 1, 2

Critical requirement: Tissue must be preserved at initial biopsy to enable PD-L1 testing 1

Serum Tumor Markers

While tissue molecular testing is mandatory for treatment selection, serum tumor markers have limited but specific roles in lung adenocarcinoma management.

Clinically Useful Serum Markers

• CEA (Carcinoembryonic Antigen): Most sensitive single marker for adenocarcinoma; useful for monitoring treatment response 5, 6, 7
• CYFRA 21-1 (Cytokeratin 19 Fragment): Second most sensitive for adenocarcinoma; valuable for therapeutic monitoring 5, 6, 7
• CA19-9 and CYFRA21-1: Elevated levels predict concordance between tissue and liquid biopsy results 8
  • CA19-9 >30 U/mL or CYFRA21-1 >6 µg/L predicts 90% concordance for actionable mutations 8
  • Combined tumor marker score >35 achieves 90% predictive threshold for tissue-blood concordance 8

Limited Clinical Applications

• Differential diagnosis: When tissue diagnosis is not possible, serum markers may assist but cannot replace histologic confirmation 5
• Prognosis: CEA and CA125 correlate with clinical stage in NSCLC 7
• Monitoring: CEA and CYFRA21-1 decrease after effective treatment and may detect early progression 7

Important limitation: Serum tumor markers should never be used to select patients for targeted therapy or replace molecular testing 5

Optimal Testing Strategy Algorithm

1. At initial diagnosis of advanced adenocarcinoma: 1

   • Obtain adequate tissue via core biopsy (preferred over cytology) 2
   • Perform H&E staining and apply TTF-1/p40 IHC if subtype unclear 2
   • Order comprehensive NGS panel (DNA and RNA) covering EGFR, ALK, ROS1, BRAF, RET, MET, ERBB2, KRAS, NTRK 1
   • Order PD-L1 testing with appropriate drug-specific assay 2
   • Results should be available within 2 weeks (10 working days) 1

2. If tissue insufficient for NGS: 1

   • Use cfDNA testing to "rule in" targetable mutations 1
   • Negative cfDNA requires tissue biopsy confirmation 1

3. At progression on EGFR TKI: 1

   • Test for EGFR T790M via cfDNA or repeat tissue biopsy 1
   • If cfDNA negative for T790M, obtain tissue confirmation 1

4. For early-stage disease (Stage I-II): 1

   • Molecular testing is encouraged but decision should be made locally 1
   • Consider testing to identify patients who may benefit from adjuvant targeted therapy 1

Critical Pitfalls to Avoid

• Never use EGFR IHC or FISH copy number to select patients for EGFR TKI therapy 1
• Never initiate ROS1-targeted therapy based on IHC alone without molecular confirmation 3
• Never use different PD-L1 assays interchangeably; each drug requires its specific companion/complementary diagnostic 1, 2
• Never rely on clinical characteristics (age, sex, smoking status) to exclude patients from molecular testing 1
• Never test multiple areas within a single tumor; one representative sample is sufficient 1
• Never use serum tumor markers to select targeted therapy 5